Agilent Technologies (NYSE:A) Upgraded to Buy by Citigroup

Agilent Technologies (NYSE:AGet Free Report) was upgraded by investment analysts at Citigroup from a “neutral” rating to a “buy” rating in a report issued on Wednesday, Briefing.com reports. The firm currently has a $150.00 price target on the medical research company’s stock, up from their previous price target of $135.00. Citigroup’s price objective would indicate a potential upside of 19.60% from the stock’s current price.

A has been the subject of several other reports. Jefferies Financial Group reissued a “hold” rating and issued a $135.00 price target (down from $152.00) on shares of Agilent Technologies in a research note on Monday, June 3rd. Bank of America boosted their price target on shares of Agilent Technologies from $134.00 to $140.00 and gave the stock a “neutral” rating in a research note on Tuesday, June 25th. Stifel Nicolaus lowered their price target on shares of Agilent Technologies from $163.00 to $151.00 and set a “buy” rating for the company in a research note on Thursday, May 30th. JPMorgan Chase & Co. lowered their price target on shares of Agilent Technologies from $165.00 to $155.00 and set an “overweight” rating for the company in a research note on Thursday, May 30th. Finally, Oppenheimer boosted their price target on shares of Agilent Technologies from $67.00 to $90.00 and gave the stock an “outperform” rating in a research note on Tuesday, March 26th. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating and ten have issued a buy rating to the company’s stock. Based on data from MarketBeat, Agilent Technologies presently has an average rating of “Moderate Buy” and an average target price of $138.06.

Check Out Our Latest Research Report on A

Agilent Technologies Stock Down 0.5 %

A opened at $125.42 on Wednesday. The company has a fifty day moving average price of $138.00 and a 200-day moving average price of $137.90. The firm has a market capitalization of $36.59 billion, a P/E ratio of 29.65, a price-to-earnings-growth ratio of 4.29 and a beta of 1.05. The company has a debt-to-equity ratio of 0.34, a current ratio of 2.15 and a quick ratio of 1.64. Agilent Technologies has a one year low of $96.80 and a one year high of $155.35.

Agilent Technologies (NYSE:AGet Free Report) last released its quarterly earnings results on Wednesday, May 29th. The medical research company reported $1.22 EPS for the quarter, beating analysts’ consensus estimates of $1.19 by $0.03. The firm had revenue of $1.57 billion during the quarter, compared to analyst estimates of $1.58 billion. Agilent Technologies had a net margin of 18.84% and a return on equity of 26.25%. The business’s revenue for the quarter was down 8.4% on a year-over-year basis. During the same period in the previous year, the business earned $1.27 EPS. Equities research analysts expect that Agilent Technologies will post 5.25 earnings per share for the current fiscal year.

Insider Activity at Agilent Technologies

In other Agilent Technologies news, CEO Padraig Mcdonnell sold 1,958 shares of the company’s stock in a transaction dated Monday, June 3rd. The shares were sold at an average price of $130.00, for a total value of $254,540.00. Following the sale, the chief executive officer now owns 25,185 shares in the company, valued at $3,274,050. The sale was disclosed in a filing with the SEC, which is available through the SEC website. In other Agilent Technologies news, SVP Dominique Grau sold 15,000 shares of the company’s stock in a transaction dated Monday, June 10th. The shares were sold at an average price of $133.28, for a total value of $1,999,200.00. Following the sale, the senior vice president now owns 49,486 shares in the company, valued at $6,595,494.08. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, CEO Padraig Mcdonnell sold 1,958 shares of the company’s stock in a transaction dated Monday, June 3rd. The stock was sold at an average price of $130.00, for a total transaction of $254,540.00. Following the completion of the sale, the chief executive officer now owns 25,185 shares in the company, valued at approximately $3,274,050. The disclosure for this sale can be found here.

Institutional Investors Weigh In On Agilent Technologies

Hedge funds and other institutional investors have recently bought and sold shares of the business. Livelsberger Financial Advisory bought a new position in Agilent Technologies in the fourth quarter worth approximately $26,000. MV Capital Management Inc. increased its stake in shares of Agilent Technologies by 120.7% in the fourth quarter. MV Capital Management Inc. now owns 192 shares of the medical research company’s stock worth $27,000 after purchasing an additional 105 shares in the last quarter. VisionPoint Advisory Group LLC purchased a new stake in shares of Agilent Technologies in the fourth quarter worth $29,000. Rise Advisors LLC increased its stake in shares of Agilent Technologies by 527.8% in the first quarter. Rise Advisors LLC now owns 226 shares of the medical research company’s stock worth $33,000 after purchasing an additional 190 shares in the last quarter. Finally, YHB Investment Advisors Inc. purchased a new stake in shares of Agilent Technologies in the first quarter worth $34,000.

About Agilent Technologies

(Get Free Report)

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.

See Also

Analyst Recommendations for Agilent Technologies (NYSE:A)

Receive News & Ratings for Agilent Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agilent Technologies and related companies with MarketBeat.com's FREE daily email newsletter.